Renzo Mancuso1, Eva Santos-Nogueira, Rosario Osta, Xavier Navarro. 1. Institute of Neurosciences and Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), E-08193 Bellaterra, Spain.
Abstract
OBJECTIVE: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by loss of motoneurons of the primary motor cortex, the brainstem and the spinal cord, for which there are not effective treatments. Several transgenic mice that mimic motoneuron disease have been used to investigate potential treatments. The objective of this work is to characterize electrophysiologically the SOD1(G93A) transgenic mouse model of ALS, and to provide useful markers to improve early detection and monitoring of progression of the disease. METHODS: We performed nerve conduction tests, motor unit number estimation (MUNE), H reflex tests and motor evoked potentials (MEPs) in a cohort of transgenic and wild type mice from 4 to 16 weeks of age. RESULTS: The results revealed dysfunction of spinal motoneurons evidenced by deficits in motor nerve conduction tests starting at 8 weeks of age, earlier in proximal than in distal muscles of the hindlimb. MUNE demonstrated that spinal motoneurons loss muscle innervation and have a deficit in their sprouting capacity. Motor evoked potentials revealed that, coexisting with peripheral deficits, there was a dysfunction of central motor tracts that started also at 8 weeks, indicating progressive dysfunction of upper motoneurons. CONCLUSIONS: These electrophysiological results provide important information about the SOD1(G93A) mouse model, as they demonstrate by the first time alterations of central motor pathways simultaneously to lower motoneuron dysfunction, well before functional abnormalities appear (by 12 weeks of age). SIGNIFICANCE: The finding of concomitant dysfunction of upper and lower motoneurons contributes to the validation of the SOD1(G93A) mouse as model of ALS, because this parallel involvement is a diagnostic condition for ALS. Electrophysiological tests can be used as early markers of the disease and to evaluate the potential benefits of new treatments on both upper and lower motoneurons.
OBJECTIVE:Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by loss of motoneurons of the primary motor cortex, the brainstem and the spinal cord, for which there are not effective treatments. Several transgenic mice that mimic motoneuron disease have been used to investigate potential treatments. The objective of this work is to characterize electrophysiologically the SOD1(G93A) transgenic mouse model of ALS, and to provide useful markers to improve early detection and monitoring of progression of the disease. METHODS: We performed nerve conduction tests, motor unit number estimation (MUNE), H reflex tests and motor evoked potentials (MEPs) in a cohort of transgenic and wild type mice from 4 to 16 weeks of age. RESULTS: The results revealed dysfunction of spinal motoneurons evidenced by deficits in motor nerve conduction tests starting at 8 weeks of age, earlier in proximal than in distal muscles of the hindlimb. MUNE demonstrated that spinal motoneurons loss muscle innervation and have a deficit in their sprouting capacity. Motor evoked potentials revealed that, coexisting with peripheral deficits, there was a dysfunction of central motor tracts that started also at 8 weeks, indicating progressive dysfunction of upper motoneurons. CONCLUSIONS: These electrophysiological results provide important information about the SOD1(G93A) mouse model, as they demonstrate by the first time alterations of central motor pathways simultaneously to lower motoneuron dysfunction, well before functional abnormalities appear (by 12 weeks of age). SIGNIFICANCE: The finding of concomitant dysfunction of upper and lower motoneurons contributes to the validation of the SOD1(G93A) mouse as model of ALS, because this parallel involvement is a diagnostic condition for ALS. Electrophysiological tests can be used as early markers of the disease and to evaluate the potential benefits of new treatments on both upper and lower motoneurons.
Authors: Pilar Larrodé; Ana Cristina Calvo; Laura Moreno-Martínez; Miriam de la Torre; Leticia Moreno-García; Nora Molina; Tomás Castiella; Cristina Iñiguez; Luis Fernando Pascual; Francisco Javier Miana Mena; Pilar Zaragoza; Santiago Ramón Y Cajal; Rosario Osta Journal: Mol Neurobiol Date: 2018-01 Impact factor: 5.590
Authors: Frank C Ko; Jia Li; Daniel J Brooks; Seward B Rutkove; Mary L Bouxsein Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2018-03-23 Impact factor: 4.092
Authors: Alex McCampbell; Tracy Cole; Amy J Wegener; Giulio S Tomassy; Amy Setnicka; Brandon J Farley; Kathleen M Schoch; Mariah L Hoye; Mark Shabsovich; Linhong Sun; Yi Luo; Mingdi Zhang; Nicole Comfort; Bin Wang; Jessica Amacker; Sai Thankamony; David W Salzman; Merit Cudkowicz; Danielle L Graham; C Frank Bennett; Holly B Kordasiewicz; Eric E Swayze; Timothy M Miller Journal: J Clin Invest Date: 2018-07-16 Impact factor: 14.808
Authors: Maria Plesia; Oliver A Stevens; Gavin R Lloyd; Catherine A Kendall; Ian Coldicott; Aneurin J Kennerley; Gaynor Miller; Pamela J Shaw; Richard J Mead; John C C Day; James J P Alix Journal: ACS Chem Neurosci Date: 2021-05-05 Impact factor: 4.418
Authors: Christopher G Wier; Alexander E Crum; Anthony B Reynolds; Chitra C Iyer; Deepti Chugh; Marilly S Palettas; Patrick L Heilman; David M Kline; W David Arnold; Stephen J Kolb Journal: Muscle Nerve Date: 2018-12-21 Impact factor: 3.217